Events - Pharvaris N.V.

Upcoming Events

Jun 26, 2026 10:00 AM EDT

2026 Annual General Meeting of Shareholders

Add to Outlook

Add to Google Calendar

Supporting Materials

2025 Annual Report 4 MB

Convening Notice and Agenda 259.8 KB

Voting Proxy 198.5 KB

Past Events

Jun 12 - Jun 15, 2026

European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026

Supporting Materials

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial 1.2 MB

Clinical Cardiovascular Safety Assessment of Oral Deucrictibant 712.7 KB

A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema 394.9 KB

Evaluations of Safety Margins and Response to Deucrictibant Extended-Release (XR) Tablet in Combination with Deucrictibant Immediate-Release (IR) Capsule 174.5 KB

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial 262.8 KB

RAPIDe-3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks 254.2 KB

Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema 202.8 KB

CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema 200.7 KB

Jun 9 - Jun 11, 2026

World Orphan Drug Congress (WODC) USA 2026

Supporting Materials

From Symptoms to Decisions: How Patient-Reported Outcomes Shape Trustworthy Clinical Evidence 13.9 MB

May 28 - May 31, 2026

2026 Eastern Allergy Conference (EAC)

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results Of The CHAPTER-1 Open-Label Extension Study 424.9 KB

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Phase 3 RAPIDe-3 Trial Results 267.1 KB

May 20, 2026 11:00 AM EDT

2026 RBC Capital Markets Global Healthcare Conference

Click for Webcast

May 17 - May 20, 2026

ISPOR 2026

Supporting Materials

Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema: Final Results of the CHAPTER-1 Open-Label Extension Study 238.4 KB

May 13, 2026 11:40 AM EDT

BofA Securities Health Care Conference 2026

Click for Webcast

May 7 - May 9, 2026

2026 EAACI Beijing Allergy School & PUMCH Allergy Symposium

Supporting Materials

Efficacy and Safety of On-Demand Treatment of Hereditary Angioedema Attacks With Oral Deucrictibant Immediate-Release Capsule: Phase 3 RAPIDe-3 Trial Results 490.1 KB

Apr 17 - Apr 19, 2026

CIIC Spring 2026 Conference

Supporting Materials

Evaluating Safety Margins of the Use of Deucrictibant Extended-Release Tablet in Combination with Deucrictibant Immediate-Release Capsule 279.7 KB

On-Demand Treatment of Hereditary Angioedema Attacks With Oral Deucrictibant Immediate-Release Capsule: Efficacy and Safety Results of the Phase 3 RAPIDe-3 Trial 364.7 KB

Mar 27 - Mar 28, 2026

2026 Global Angioedema Leadership Conference

Supporting Materials

Results of the Phase 3 RAPIDe-3 Study of Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks 283.7 KB

End of Progression of Hereditary Angioedema Attacks with Oral Deucrictibant Immediate-Release Capsule: RAPIDe-3 Phase 3 Trial 270.9 KB

CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema 223.9 KB

Lived Patient Experiences of Hereditary Angioedema Based on Attacks and Associated Symptoms: An Innovative Conceptual Model 375.8 KB

Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema 233.3 KB

Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema (presentation) 560 KB

Mar 19 - Mar 21, 2026

Italian Network for Hereditary and Acquired Angioedema (ITACA) 5th ITACA National Congress

Supporting Materials

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Phase 3 RAPIDe-3 Trial Results 267.6 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the CHAPTER-1 Open-Label Extension Study 450.9 KB

Pagination

Current page 1
Page 2
Page 3
…
Next page
Last page

Presentations

Latest Corporate Presentation